Frontiers in Pharmacology (Aug 2022)

Recent advances of IDH1 mutant inhibitor in cancer therapy

  • Wangqi Tian,
  • Weitong Zhang,
  • Yifan Wang,
  • Ruyi Jin,
  • Yuwei Wang,
  • Hui Guo,
  • Yuping Tang,
  • Xiaojun Yao

DOI
https://doi.org/10.3389/fphar.2022.982424
Journal volume & issue
Vol. 13

Abstract

Read online

Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans. In recent years, mutations in IDH have been observed in several tumors, including glioma, acute myeloid leukemia, and chondrosarcoma. Among them, the frequency of IDH1 mutations is higher than IDH2. IDH1 mutations have been shown to increase the conversion of α-KG to 2-hydroxyglutarate (2-HG). IDH1 mutation-mediated accumulation of 2-HG leads to epigenetic dysregulation, altering gene expression, and impairing cell differentiation. A rapidly emerging therapeutic approach is through the development of small molecule inhibitors targeting mutant IDH1 (mIDH1), as evidenced by the recently approved of the first selective IDH1 mutant inhibitor AG-120 (ivosidenib) for the treatment of IDH1-mutated AML. This review will focus on mIDH1 as a therapeutic target and provide an update on IDH1 mutant inhibitors in development and clinical trials.

Keywords